BIO-Europe more popular than ever
More than 4,000 participants from all over the globe visited Berlin in early November to take part in this years BIO-Europe. The event continues to be on the upswing […]
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1081 entries already.
Entries by Thomas Gabrielczyk
300 jobs more: US company expands its Irish campus
/in News/by Thomas GabrielczykUS biotech company Regeneron Pharmaceuticals revealed plans to create some 300 new jobs in Ireland’s Limerick County. The jobs form part of a US$100m (85m) expansion plan for the company’s […]
Immunethep receives grant from Gates Foundation
/in News/by Thomas GabrielczykPortuguese biotech company Immunethep has convinced the Bill & Melinda Gates Foundation to hand out a grant to test its antibody against the bacterial extracellular virulence factor GAPDH.
Uniqure readies share stock offering
/in News/by Thomas GabrielczykDutch Uniqure BV launched a public offering of five million shares of common stock. Underwriters over-allotment will be an additional 750,000 shares.
Voluntary health agency jump-starts Selvitas SEL120 programme
/in News/by Thomas GabrielczykThe Leukemia & Lymphoma Society (LLS) and Polish drug developer Selvita SA have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients […]
Uniqures new COO to oversee GMP
/in News/by Thomas GabrielczykGene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current […]
Hansas immunomodulatory enzyme does the job
/in News/by Thomas GabrielczykSweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
J&J intensifies vaccine endeavour with Bavarian Nordic
/in News/by Thomas GabrielczykJohnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
GSK cancels 30 preclinical and clinical programmes
/in News/by Thomas GabrielczykUKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and […]
Ablynx adds Sanofi to its list of pharma partners
/in News/by Thomas GabrielczykBelgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth 2.4bn but comes with an upfront payment of just 23m. The partners […]